DOCSLIB.ORG

Comparison of Doxycycline and Minocycline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparison of Doxycycline and Minocycline Table. Comparison of Doxycycline and Minocycline 18-20,37-44 Characteristics Doxycycline Minocycline How supplied Doxycycline monohydrate Minocycline hydrochloride Tablets: 50 mg, 75 mg, 100 mg, 150 mg Tablets: 50 mg, 75 mg, 100 mg Capsules: 50 mg, 100 mg, 150 mg Capsules: 50 mg, 75 mg, 100 mg Capsule extended- release: 40 mg Extended release tablets: 45 mg, 90 mg, Suspension: 25 mg/5 mL 135 mg Doxycycline hyclate Solodyn extended release tablets: 55 mg, Tablets: 20 mg, 100 mg 65 mg, 80 mg, 105 mg, 115 mg Delayed release tablets: 75 mg, 100 Subgingival: 1 mg mg, 150 mg Injection: 100 mg Capsules: 50 mg, 100 mg Injection: 100 mg Doxycycline Calcium Syrup: 50 mg/5 mL Bioavailability 90% to 100% 90% to 100% Time to peak 1.5 to 4 hours 1.5 to 4 hours Half-life 15 to 24 hours 11 to 22 hours Protein binding 82% - 93% 76% Metabolism Liver Liver Elimination Kidney: 20% to 30% Kidney: 10% to 13% Feces: 70% to 80% Feces: 19% Tissue Penetration Doxycycline is 5 times more lipophilic Minocycline is 5 times more lipophilic than than tetracycline doxycycline. Minocycline achieves highest penetration into saliva and cerebrospinal fluid compared to doxycycline and tetracycline. Dosage Dosage depends on indication for use. Dosage depends on indication for use. Adverse reactions Doxycycline may be associated with Minocycline may be associated with more more GI upset than minocycline. GI vestibular, autoimmune, hepatic and upset may vary with doxycycline hypersensitivity reactions than doxycycline. formulation. Common Adverse Frequency not given in labeling or • Gastrointestinal distress (dyspepsia, Drug Reactions tertiary references. anorexia, nausea, dysphagia) • Gastrointestinal distress (dyspepsia, • Arthralgia (1%) anorexia, nausea, dysphagia) • Myalgia (1%) • Glossitis • Headache (23%) • Skin rashes • Dizziness (9%) • Photosensitivity • Vertigo (1%) • Vaginal candidiasis • Tinnitus (2%) • Urticaria (2%) Note: only the Oracea product labeling • Pruritus (5%) reports incidence of adverse reactions • Malaise (4%) and that is for doxycycline 40 mg daily. • Somnolence (2%) The following reactions occurred at > • Fatigue (9%) 2% and more than placebo with • Fever Oracea: Diarrhea 5%, nasopharyngitis • Skin rashes 5%, sinusitis 3%, and hypertension 3%. • Photosensitivity • Vaginal candidiasis Serious Adverse • Benign intracranial hypertension • Benign intracranial hypertension Drug Reactions • Exfoliative dermatitis, • Exfoliative dermatitis • Hypersensitivity reactions • Hypersensitivity reactions • Lupus-like syndrome • Lupus-like syndrome Table. Comparison of Doxycycline and Minocycline 18-20,37-44 Characteristics Doxycycline Minocycline • Blood dyscrasias • Blood dyscrasias • Hepatotoxicity • Hepatotoxicity • Esophageal ulceration • Esophageal ulceration • Pseudomembranous colitis • Pseudomembranous colitis • Hyperpigmentation Warnings • Tooth discoloration in forming teeth • Tooth discoloration in forming teeth • Do not use in pregnancy • Do not use in pregnancy • Photosensitivity – dependent on dose, • Decrease dose in renal impairment UVA intensity, and skin type • Photosensitivity – dependent on dose, • Potential overgrowth of UVA intensity, and skin type nonsusceptible organisms including • CNS effects like vertigo, dizziness or fungi light-headedness can occur – use • Pseudomembranous colitis and caution with driving and operating Clostridium difficile associated hazardous equipment diarrhea • Potential overgrowth of nonsusceptible • Benign intracranial hypertension, organisms pseudotumor cerebri • Pseudomembranous colitis and C. • Autoimmune syndromes- tetracyclines difficile infection have been associated with • Hepatotoxicity autoimmune syndromes • Benign intracranial hypertension, • Tissue hyperpigmentation pseudotumor cerebri • Development of drug resistant • Autoimmune syndromes – minocycline is bacteria associated with drug induced lupus like syndrome, autoimmune hepatitis and vasculitis. • Hypersensitivity reactions including DRESS syndrome • Tissue hyperpigmentation • Development of drug resistant bacteria Labeled Indication • Acne • Acne Adult Patients, • In patients with penicillin allergy, • In patients with penicillin allergy, Based on Product treatment of uncomplicated gonorrhea treatment of Neisseria gonorrhoeae, Labeling for Oral from Neisseria gonorrhoeae, Syphilis Syphilis from Treponema pallidum, Yaws Doxycycline and from Treponema pallidum, Yaws from from Treponema pertenue, Listeriosis Minocycline Treponema pertenue, Listeriosis from from Listeria monocytogenes, Vincent’s Listeria monocytogenes, Vincent’s infection from Fusobacterium fusiforme, infection from Fusobacterium Actinomycosis from Actinomyces Israelii, fusiforme, Actinomycosis from and infections from Clostridium species Actinomyces Israelii, and infections • Adjunct treatment of amebic dysentery from Clostridium species • Anthrax treatment in patients with • Adjunct treatment of amebic penicillin contraindication dysentery • Bacterial infection caused by: Chlamydia • Anthrax due to Bacillus anthracis, trachomatis, Chlamydia psittaci, Borrelia including post-exposure treatment. recurrentis, Haemophilus ducreyi, • Bacterial infection caused by: Yersinia pestis, Francisella tularensis, Chlamydia trachomatis, C. psittaci, Vibrio cholerae, Campylobacter fetus, Borrelia recurrentis, Haemophilus Brucella species, Bartonella bacilliformis, ducreyi, Yersinia pestis, Francisella Calymmatobacterium granulomatis, tularensis, Vibrio cholerae, Escherichia coli, Enterobacter Campylobacter fetus, Brucella aerogenes, Shigella species, species, Bartonella bacilliformis, Acinetobacter species. Calymmatobacterium granulomatis, • Rickettsial disease Escherichia coli, Enterobacter • Skin and skin structure infections from S. Table. Comparison of Doxycycline and Minocycline 18-20,37-44 Characteristics Doxycycline Minocycline aerogenes, Shigella species, aureus. However, not drug of choice for Acinetobacter species. any type of staphylococcal infection. • Rickettsial disease • Treatment of asymptomatic carriers of • Respiratory tract infection caused by Neisseria meningitidis. Mycoplasma pneumoniae, • Adjunct treatment of periodontitis Streptococcus pneumoniae, (Arestin®) Haemophilus influenzae and • Respiratory tract infection caused by Klebsiella species Mycoplasma pneumoniae, Streptococcus • Treatment of rosacea in adult patients pneumoniae, Haemophilus influenzae (Oracea®) and Klebsiella species • Skin and skin structure infections from • Uncomplicated Ureaplasma urealyticum S. aureus. However, not drug of infection choice for any type of staphylococcal • Urinary tract infection from Klebsiella infection. species • Urethritis from Ureaplasma urealyticum infection (non- gonococcal) • Urinary tract infection from Klebsiella species • Prophylaxis of Plasmodium falciparum .
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Erythromycin Versus Tetracycline for Treatment of Mediterranean Spotted Fever
    Arch Dis Child: first published as 10.1136/adc.61.10.1027 on 1 October 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 1027-1029 Erythromycin versus tetracycline for treatment of Mediterranean spotted fever T MUNOZ-ESPIN, P LOPEZ-PARtS, E ESPEJO-ARENAS, B FONT-CREUS, I MARTINEZ- VILA, J TRAVERIA-CASANOVA, F SEGURA-PORTA, AND F BELLA-CUETO Hospital de Sant Llatzer, Terrassa, Clinica Infantil del Nen Jesus, Sabadell, and Hospital Mare de Deu de la Salut, Sabadell, Barcelona, Spain SUMMARY Eighty one children aged between 1 and 13 years participated in a randomised comparative trial of tetracycline hydrochloride and erythromycin stearate for treatment of Mediterranean spotted fever. Both therapeutic regimens proved effective, but in patients treated with tetracycline both clinical symptoms and fever disappeared significantly more quickly. Likewise, when those patients who began treatment within the first 72 hours of illness are considered the febrile period had a significantly shorter duration in the group treated with tetracycline. One patient was switched to tetracycline because there was no improvement of clinical manifestations, with persistence of fever, myalgias, and prostration, after receiving eight days of treatment with erythromycin. These results suggest that tetracyclines are superior to erythromycin in the treatment of Mediterranean spotted fever. copyright. Mediterranean spotted fever is an acute infectious were not included in the trial; neither were those disease caused by Rickettsia conorii. During the
    [Show full text]
  • Use of Antibiotics to Prevent Calf Diarrhea and Septiceinia
    PEER REVIEWED Use of Antibiotics to Prevent Calf Diarrhea and Septiceinia Peter D. Constable, BVSc, PhD, DACVIM Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802 Abstract l'oxytetracycline (0.15 to 6.0 mg/lb [0.32 to 13.2 mg/kg] au 24 h, per os) sont efficaces dans le traitement de la This article reviews studies related to the use of diarrhee chez les veaux et permettent un accroissement antimicrobial agents to prevent calf diarrhea and septi­ du taux de croissance des veaux nourris au lait. De cemia, and discusses whether prophylactic administra­ plus, la chlortetracycline permet la diminution du taux tion of antibiotics in neonatal calves is effective and de mortalite lorsque administree chez les veaux indicated. Orally administered chlortetracycline, oxytet­ nouveau-nes pour prevenir la diarrhee. 11 n'y a pas racycline, tetracycline and neomycin have label claims d'antibiotiques qui promettent de prevenir la in the US for the "control" or "aid in the control" of calf septicemie chez les veaux. Paree qu'il ne semble pas diarrhea caused by bacteria susceptible to the antibi­ exister d'etudes sur l'efficacite de la tetracycline et de otic. Chlortetracycline and oxytetracycline (0.15 to 6.0 la neomycine et parce que !'utilisation hors homologa­ mg/lb [0.32 to 13.2 mg/kg], q 24 h, PO) are efficacious tion des medicaments. n'est pas permise pour la for preventing calf diarrhea and increasing growth rate prevention routiniere des maladies ou !'augmentation in milk-fed calves, and chlortetracycline (3 mg/lb [7 mg/ du taux de croissance et du taux de conversion kg], q 12 h, PO) is efficacious for decreasing mortality alimentaire, selon le code de l'AMDUCA de 1994, seule when administered to prevent diarrhea in neonatal !'administration orale de chlortetracycline et calves.
    [Show full text]
  • Minocycline-Minocin-Fact-Sheet.Pdf
    Minocycline PATIENT FACT SHEET (Minocin) Minocycline (minocin) is an anti-inflammatory antibiotic sometimes used to treat mild rheumatoid arthritis (RA). It belongs to the group of antibiotics, called tetracycline, which are typically used to treat infections. Although RA is not thought to be caused by an infection, minocycline may improve the signs and symptoms of this disease. Because it has been studied less and may be less effective than other options, it is not as commonly prescribed in RA. WHAT IS IT? Minocycline is usually taken as a 100 mg capsule twice a day. It may be taken with food but should not be taken with other medications such as antacids or iron tablets. It has a slow onset and may take several months to work. HOW TO TAKE IT The most common side effects from this medicine rare cases, minocycline can cause drug-induced lupus, are gastrointestinal upset, dizziness, and skin rash. but this condition usually improves after stopping Patients who take this medication for a long time may the medication. notice changes in their skin color, but this usually Minocycline is passed into breast milk, so mothers resolves after stopping the medication. Some women should avoid breast-feeding in order to prevent delayed who take minocycline develop vaginal yeast infections. development of teeth and bones in their infants. Minocycline may increase sensitivity to sunlight, resulting Minocycline can increase a nursing infant’s risk of fungal in more frequent sunburns or the development of rashes infections or dizziness. Because minocycline may cause SIDE following sun exposure. Avoiding prolonged sun exposure discoloration of teeth and problems with bone growth in and sunscreen is recommended.
    [Show full text]
  • Sexually Transmitted Diseases Treatment Options
    Sexually transmitted disease (STD) treatment options PREFERRED & ALTERNATIVE OPTIONS Many clinical partners are operating in a limited capacity during the COVID-19 pandemic. Below are preferred (in clinic or other location where injections can be given) and alternative (when only oral medicines are available 1) treatments for STDs. Syndrome Preferred Treatments Alternative Treatments Follow-up Male urethritis syndrome Ceftriaxone 250mg intramuscular (IM) x 1 PLUS Men who have sex with men (MSM) and transgender women2: Patients should be counseled to azithromycin 1g PO x 1 Cefixime 800 mg PO x 1 PLUS doxycycline 100 mg PO BID x 7 days be tested for STDs once clinical Presumptively treating: care is resumed in the local If azithromycin is not available: doxycycline 100 Men who have sex with women only: gonorrhea clinics. Clients who have been mg PO BID for 7 days (except in pregnancy3) Cefixime 800mg PO x 1 PLUS azithromycin 1g PO x 1 referred for oral treatment If cephalosporin allergy5 is reported, gentamicin If cefixime is unavailable, substitute cefpodoxime 400mg PO q12h should return for 240mg IM x 1 PLUS azithromycin 2g PO x 1 x 2 for cefixime in above regimens4 comprehensive testing and screening and linked to services If oral cephalosporin not available or history of cephalosporin at that time. allergy5: azithromycin 2g PO x 1 If azithromycin is not available: doxycycline 100 mg PO BID for 7 days (except in pregnancy3) Patients should be advised to abstain from sex for 7 days Treatment typically guided by examination and For presumptive therapy when examination and laboratory following completion of Vaginal discharge syndrome treatment.
    [Show full text]
  • Delayed Dosing of Minocycline Plus N-Acetylcysteine Reduces Neurodegeneration in Distal Brain Regions and Restores Spatial Memor
    Manuscript bioRxiv preprint doi: https://doi.org/10.1101/2021.03.28.437090; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Delayed dosing of minocycline plus N-acetylcysteine reduces neurodegeneration in distal brain regions and restores spatial memory after experimental traumatic brain injury Kristen Whitney 1,2, Elena Nikulina1, Syed N. Rahman1, Alisia Alexis1 and Peter J. Bergold1,2 1Department of Physiology and Pharmacology 2Program in Neural and Behavioral Science, School of Graduate Studies State University of New York-Downstate Health Sciences University, Brooklyn NY 11215 Corresponding Author: [email protected] Department of Physiology and Pharmacology, Box 29 State University of New York – Downstate Health Sciences University 450 Clarkson Avenue Brooklyn, NY 11215 Declarations of interest: none Abbreviations: CHI- closed head injury Contra- contralateral Ipsi- ipsilateral MAP2 -microtubule associated protein 2 MINO- minocycline MN12- MINO plus NAC first dosed 12 hours after injury MN72- MINO plus NAC first dosed 72 hours after injury NAC- N-acetylcysteine TBI- Traumatic brain injury 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.28.437090; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Multiple drugs to treat traumatic brain injury (TBI) have failed clinical trials. Most drugs lose efficacy as the time interval increases between injury and treatment onset. Insufficient therapeutic time window is a major reason underlying failure in clinical trials.
    [Show full text]
  • Minocycline Synergizes with N-Acetylcysteine and Improves Cognition and Memory Following Traumatic Brain Injury in Rats
    Minocycline Synergizes with N-Acetylcysteine and Improves Cognition and Memory Following Traumatic Brain Injury in Rats Samah G. Abdel Baki, Ben Schwab, Margalit Haber, Andre´ A. Fenton, Peter J. Bergold* Departments of Physiology and Pharmacology, State University of New York-Downstate Medical Center, Brooklyn, New York, United States of America Abstract Background: There are no drugs presently available to treat traumatic brain injury (TBI). A variety of single drugs have failed clinical trials suggesting a role for drug combinations. Drug combinations acting synergistically often provide the greatest combination of potency and safety. The drugs examined (minocycline (MINO), N-acetylcysteine (NAC), simvastatin, cyclosporine A, and progesterone) had FDA-approval for uses other than TBI and limited brain injury in experimental TBI models. Methodology/Principal Findings: Drugs were dosed one hour after injury using the controlled cortical impact (CCI) TBI model in adult rats. One week later, drugs were tested for efficacy and drug combinations tested for synergy on a hierarchy of behavioral tests that included active place avoidance testing. As monotherapy, only MINO improved acquisition of the massed version of active place avoidance that required memory lasting less than two hours. MINO-treated animals, however, were impaired during the spaced version of the same avoidance task that required 24-hour memory retention. Co- administration of NAC with MINO synergistically improved spaced learning. Examination of brain histology 2 weeks after injury suggested that MINO plus NAC preserved white, but not grey matter, since lesion volume was unaffected, yet myelin loss was attenuated. When dosed 3 hours before injury, MINO plus NAC as single drugs had no effect on interleukin-1 formation; together they synergistically lowered interleukin-1 levels.
    [Show full text]
  • An Electronic Medical Records-Based Approach to Identify Idiosyncratic
    www.nature.com/scientificreports OPEN An electronic medical records- based approach to identify idiosyncratic drug-induced liver injury in children Tracy L. Sandritter1, Jennifer L. Goldman1,2, Clayton J. Habiger3, James F. Daniel4, Jennifer Lowry1 & Ryan T. Fischer 4* Drug-induced liver injury (DILI) is the leading cause of liver failure in the United States and the most common cause of drug recall. As opposed to the recognized direct toxicity of super-therapeutic acetaminophen or chemotherapeutic agents in children, limited data exists for pediatric populations on the incidence of idiosyncratic DILI (iDILI) that may develop independently of drug dose or duration of administration. To improve the detection of adverse drug reactions at our hospital, we utilized electronic medical records-based automated trigger tools to alert providers of potential iDILI. Clinical criteria concerning for iDILI were defned as serum ALT > 5x or serum bilirubin > 1.5x upper limit of normal in the setting of medication exposure. Over a two year period, 12 patients were identifed as having possible or probable iDILI. Out of the identifed patients, three were males, and the mean age was 10.8 years. Implicated agents included eight antibiotics, two anti-epileptics, one anti-psychotic, and one anti-infammatory medication. Roussel-Uclaf Causality Assessment Methods identifed one “possible” case, 11 “probable” cases, and one “highly probable” case of iDILI. Improved awareness and more vigilant programming can generate better data on iDILI and improve our understanding of the condition and its incidence in children. Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the United States1 and the most common cause of drug recall from the market2.
    [Show full text]
  • UC San Diego UC San Diego Electronic Theses and Dissertations
    UC San Diego UC San Diego Electronic Theses and Dissertations Title Human in vitro model of neuro-inflammation Permalink https://escholarship.org/uc/item/00k7p6dr Author Boyer, Leah Anne Publication Date 2013 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA SAN DIEGO Human in vitro model of neuro-inflammation A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Biomedical Sciences by Leah Anne Boyer Committee in charge: Professor Fred H. Gage, Chair Professor Lawrence S.B. Goldstein, Co-Chair Professor Christopher K. Glass Professor Eliezer Masliah Professor Alysson R. Muotri 2013 Copyright Leah Anne Boyer, 2013 All rights reserved The Dissertation of Leah Anne Boyer is approved, and it is acceptable in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California, San Diego 2013 iii TABLE OF CONTENTS Signature Page……………………………………………...…………………. iii Table of Contents………………………………………………………...……. iv List of Abbreviations………………………………………………………...…. vii List of Figures……………………………………………………...…………… ix Acknowledgements…………………………………………………...……….. xi Vita…………………………………………………………………………...….. xiii Abstract of the Dissertation……………………………………………………. xv Chapter 1. Differentiation of human pluripotent stem cells into neural subtypes enriched for dopaminergic neurons…………………...…………… 1 Abstract………………………………………………………….………….. 1 Background and Significance…………………………………………….
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • Doxycycline/Minocycline Step Therapy Criteria Program Summary
    Doxycycline/Minocycline Step Therapy Criteria Program Summary This criteria applies to Commercial, NetResults F series and Health Insurance Marketplace formularies. OBJECTIVE The intent of the Doxycycline/Minocycline Step Therapy (ST) program is to encourage the use of both cost-effective preferred doxycycline and minocycline products prior to the use of nonpreferred brand or generic doxycycline or minocycline products and to accommodate for use of brand nonpreferred doxycycline or minocycline products when the generic products cannot be used due to previous trial, documented intolerance, FDA labeled contraindication, or hypersensitivity. Requests for nonpreferred doxycycline and minocycline products will be reviewed when patient-specific documentation has been provided. TARGET DRUGS Doxycycline Products: Acticlate™ (doxycycline hyclate tablet) Adoxa (doxycycline monohydrate tablet, capsule) Doryx, Doryx MPC® (doxycycline hyclate delayed-release tablet)a Doxycycline (doxycycline hyclate delayed-release capsulea, doxycycline hyclate tablet, doxycycline monohydrate delayed release capsule) Monodox (doxycycline monohydrate capsule) Oracea (doxycycline monohydrate delayed-release capsule) Vibramycin (doxycycline hyclate capsule, doxycycline monohydrate suspension, doxycycline calcium syrup Minocycline Products: Minocin (minocycline capsule) minocycline tablet Solodyn (minocycline extended-release tablet)a a - available as a generic; designated target PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Brand and Nonpreferred generic doxycycline and minocycline products will be approved when BOTH of the following are met: 1. ONE of the following: a. The patient’s medication history includes use of a preferred generic doxycycline product OR b. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a preferred generic doxycycline product AND 2. ONE of the following is met: a. The patient’s medication history includes use of a preferred generic minocycline product OR b.
    [Show full text]